TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05386238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral weight loss program
Description: 16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral weight loss program
Description: 16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
Study: NCT05270109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BiZact
Description: In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Steel
Description: In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery.
Study: NCT05449158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left atrial pressure regulation
Description: For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
Study: NCT05748522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Mobility
Description: t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diaphragmatic Breathing
Description: The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist.
Study: NCT05361811

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: 8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
Study: NCT06043921

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention associated with this observational study.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention associated with this observational study.
Study: NCT06532266

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TechTrade Ready Heat Half Body Temperature Management Blankets
Description: The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 3 layers of 100% cotton woven blankets
Study: NCT06534801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone will be administered intravenously in the group 1
Description: Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone will be administered intravenously in the group 1
Description: Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
Study: NCT06110312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavCare-EU
Description: NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
Study: NCT05866471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous auricular Vagus Nerve Stimulation (taVNS)
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Support Alone
Description: Participants assigned to Psychosocial Support Alone will not receive taVNS following psilocybin dosing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taVNS
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham taVNS
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham taVNS
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
Study: NCT04905901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Normal saline placebo nebulization 15 minutes before sinus surgery
Study: NCT05399784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early postpartum visit
Description: The early postpartum visit will be an in-person visit with a medical provider at 14-21 days postpartum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard postpartum visit
Description: The standard postpartum visit will occur at 35 to 56 days postpartum.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard postpartum visit
Description: The standard postpartum visit will occur at 35 to 56 days postpartum.
Study: NCT05361811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Intervention
Description: 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT Intervention
Description: 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
Study: NCT06063629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous drain
Description: The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No drain
Description: No drain will be inserted into patients allocated to this group
Study: NCT06318676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days
Study: NCT05473195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVL-GSK098 9mg
Description: BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVL-GSK098 9mg
Description: BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVL-GSK098 9mg
Description: BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250mg
Description: Ethionamide 250 mg po OD (Eto250)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250mg
Description: Ethionamide 250 mg po OD (Eto250)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250mg
Description: Ethionamide 250 mg po OD (Eto250)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250mg
Description: Ethionamide 250 mg po OD (Eto250)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250 mg
Description: Ethionamide 750 mg po given in a single or divided dose (Eto750)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethionamide 250 mg
Description: Ethionamide 750 mg po given in a single or divided dose (Eto750)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 MG
Description: Isoniazid 300 mg po OD (INH)
Study: NCT05412862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
Study: NCT05824832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interscalene block with the addition of buprenorphine, clonidine, dexamethasone
Description: Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block with buprenorphine alone
Description: Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
Study: NCT06628167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation
Description: Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduling
Description: Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
Study: NCT06714929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydration
Description: Clusters of schools will sequentially be exposed to the intervention in a stepped-wedge fashion. The intervention is a 4-month community participatory school-based hydration intervention that includes provision of refillable water bottles in schools with hydration stations in addition to: 1) social marketing, 2) behavioral reinforcement, and 3) education and outreach.
Study: NCT06721143

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AION-301
Description: AION-301 Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Infusion
Study: NCT05630001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
Study: NCT05786521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Lifestyle Counseling will be provided throughout study intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Lifestyle Counseling will be provided throughout study intervention
Study: NCT04981405

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccines
Description: Gam-COVID-Vac EpiVacCorona COVIVAC

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccines
Description: Gam-COVID-Vac EpiVacCorona COVIVAC
Study: NCT06382220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: drug injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: drug injection
Study: NCT05199207

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity programm
Description: adapted physical activity during 3 month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity programm
Description: adapted physical activity during 3 month
Study: NCT05165017

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AlloRx Stem Cells®
Description: Umbilical cord-derived allogeneic mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo infusion without mesenchymal stem cells
Study: NCT04717869

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 2D ultrasound image collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker Analysis
Description: Inflammatory and nutritional biomarker analysis

Intervention type: OTHER
Intervention: Frailty Index
Description: A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
Study: NCT06720038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the low dose VAX-31
Description: 31 valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the mid dose VAX-31
Description: 31 valent pneumococcal conjugate vaccine
Study: NCT05044832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Music
Description: Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
Study: NCT04208529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: CTX001 infusion.
Study: NCT06569693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) Program
Description: MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study: NCT06185556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible electroporation
Description: Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
Study: NCT06079853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PureSomni Sleep Health Product Kit
Description: PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
Study: NCT05630885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC 150 mg
Description: Administered as one 150-mg tablet by mouth once a day with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC 300 mg
Description: Administered as two 150-mg tablets by mouth once a day with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CVC 150 mg
Description: Administered as one 150-mg matching placebo tablets by mouth once a day with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CVC 300 mg
Description: Administered as two 150-mg matching placebo tablets by mouth once a day with food.
Study: NCT05349188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
Study: NCT06573398

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
Description: Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
Study: NCT05009563

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET/CT
Description: whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
Study: NCT04828759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-treatment
Description: The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
Study: NCT05349188

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 0.5 mg
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose placebo pill
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
Study: NCT05292313

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single distal femur implant
Description: Single implant fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual distal femur implants
Description: Dual implant fixation
Study: NCT06094543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Tool
Description: 8 week daily patient education and engagement tool
Study: NCT05383976

Intervention type: OTHER
Intervention: Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program
Description: This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
Study: NCT06360198

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was applied to the group.